Akebia Therapeutics, Inc. 8-K

What Happened
Akebia Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 in a press release issued May 7, 2026. The company filed a Current Report on Form 8-K (Item 2.02) to furnish that press release (Exhibit 99.1), which is incorporated by reference into the filing. The report was signed by President and CEO John P. Butler.

Key Details

• Filing date: May 7, 2026; quarter reported: Q1 2026 (ended March 31, 2026).
• Item reported: 2.02 — Results of Operations and Financial Condition (press release furnished as Exhibit 99.1).
• Exhibit included: Press Release dated May 7, 2026 (Exhibit 99.1) and Inline XBRL cover page (Exhibit 104).
• Authorized signatory: John P. Butler, President and Chief Executive Officer.

Why It Matters
This 8-K alerts investors that Akebia has published its quarterly earnings and business highlights; those details (revenue, net income/loss, cash position, and any guidance or business updates) will be in the accompanying press release. Retail investors should review the Exhibit 99.1 press release and the company’s subsequent filings for the specific financial figures and any management commentary that could affect the stock or near-term outlook.